Blood test for early cancer detection using RNA analysis
A Blinded Prospective Study on Development and Validation of the Blood Cell RNA-Based Cancer Detection
This study is testing a blood test that looks at RNA to see if it can help find cancer earlier in people who have just been diagnosed and compare it to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05839834 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve early cancer diagnosis by analyzing RNA from blood cells of newly diagnosed cancer patients and healthy donors. By collecting peripheral blood samples, researchers will develop a model to differentiate between cancer patients and healthy individuals based on RNA profiles. The study will measure the accuracy of this model using metrics such as the area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity. The goal is to enhance early detection methods for multiple types of cancer, potentially leading to better treatment options and outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years or older who have recently been diagnosed with cancer.
Not a fit: Patients who are pregnant, have received a blood transfusion within the last month, or have a known prior diagnosis of cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier cancer detection, providing patients with more treatment options and potentially improving survival rates.
How similar studies have performed: While there have been various studies on cancer detection methods, this specific RNA-based approach is relatively novel and has not been extensively tested in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for All the Participants 1. Age 18 years or older 2. Provide informed consent Exclusion Criteria for All the Participants: 1. Pregnancy or lactating women 2. Received a blood transfusion within 1 month 3. Received anti-cancer treatment within 3 years 4. Known prior diagnosis of cancer 5. Poor health status or unfit to tolerate blood draw
Where this trial is running
Wuhan, Hubei
- Zheng Wang — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Zheng Wang, MD/PhD
- Email: zhengwang@hust.edu.cn
- Phone: +86 27 85726612
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.